- Home
- NEXN vs ETNB Comparison
NEXN vs ETNB Comparison
Compare NEXN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEXN
- ETNB
- Stock Information
- Founded
- NEXN 2007
- ETNB 2018
- Country
- NEXN Israel
- ETNB United States
- Employees
- NEXN N/A
- ETNB N/A
- Industry
- NEXN Computer Software: Programming Data Processing
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- NEXN Technology
- ETNB Health Care
- Exchange
- NEXN Nasdaq
- ETNB Nasdaq
- Market Cap
- NEXN 645.6M
- ETNB 773.7M
- IPO Year
- NEXN 2021
- ETNB 2019
- Fundamental
- Price
- NEXN $9.75
- ETNB $9.01
- Analyst Decision
- NEXN Buy
- ETNB Buy
- Analyst Count
- NEXN 6
- ETNB 7
- Target Price
- NEXN $10.33
- ETNB $30.33
- AVG Volume (30 Days)
- NEXN 128.1K
- ETNB 2.4M
- Earning Date
- NEXN 03-05-2025
- ETNB 02-27-2025
- Dividend Yield
- NEXN N/A
- ETNB N/A
- EPS Growth
- NEXN N/A
- ETNB N/A
- EPS
- NEXN 0.09
- ETNB N/A
- Revenue
- NEXN $349,109,000.00
- ETNB N/A
- Revenue This Year
- NEXN $7.66
- ETNB N/A
- Revenue Next Year
- NEXN $7.80
- ETNB N/A
- P/E Ratio
- NEXN $44.21
- ETNB N/A
- Revenue Growth
- NEXN 1.55
- ETNB N/A
- 52 Week Low
- NEXN $4.61
- ETNB $5.99
- 52 Week High
- NEXN $10.94
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- NEXN 48.64
- ETNB 69.31
- Support Level
- NEXN $9.21
- ETNB $5.99
- Resistance Level
- NEXN $10.05
- ETNB $11.77
- Average True Range (ATR)
- NEXN 0.27
- ETNB 0.71
- MACD
- NEXN -0.09
- ETNB 0.28
- Stochastic Oscillator
- NEXN 31.41
- ETNB 52.28
About NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd empowers advertisers, agencies, publishers, and broadcasters to utilize video and connected TV. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with advanced and exclusive data at its core.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).